Selection of neoadjuvant treatment based on oncotype score in luminal breast cancer

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S72
Author(s):  
A. Gasol Cudos ◽  
S. Morales Murillo ◽  
J. Veas Rodriguez ◽  
C. Canosa Morales ◽  
J. Melé Olivé ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Treatment ◽  
Luminal Breast Cancer ◽  
Selection Of

scholarly journals Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

The Breast ◽  
2021 ◽  
Vol 56 ◽  
pp. 35-41
Author(s):  
Serafin Morales Murillo ◽  
Ariadna Gasol Cudos ◽  
Joel Veas Rodriguez ◽  
Carles Canosa Morales ◽  
Jordi Melé Olivé ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Treatment ◽  
Luminal Breast Cancer ◽  
Test Results ◽  
Gene Test ◽  
Selection Of

scholarly journals Reply: 18 F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer

2016 ◽  
Vol 58 (4) ◽  
pp. 683.2-684
Author(s):  
Sun Young Chae ◽  
Sung-Bae Kim ◽  
Sei Hyun Ahn ◽  
Dae Hyuk Moon
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Treatment ◽  
Luminal Breast Cancer

scholarly journals Strategy of post-neoadjuvant treatment of patients with residual breast cancer

2020 ◽  
Vol 16 (1) ◽  
pp. 43-54
Author(s):  
V. V. Semiglazov ◽  
A. A. Natopkin
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Systemic Treatment ◽  
Neoadjuvant Treatment ◽  
Breast Tumors ◽  
Recurrence Risk ◽  
Molecular Profile ◽  
Malignant Breast ◽  
Selection Of ◽  
Biological Subtype

The article considers the aspects of selection of post-neoadjuvant therapy for patients with residual breast cancer depending on biological subtype and molecular profile of the tumor. Analysis of morphological and molecular markers allowing to evaluate sensitivity of malignant breast tumors with high recurrence risk to new types of systemic treatment is presented.

RELATIONS OF PROTEASOMAL SYSTEM WITH TUMOR STAGE IN LUMINAL BREAST CANCER

2018 ◽  
Vol 64 (2) ◽  
pp. 218-221
Author(s):  
Yelena Shashova ◽  
Natalya Tarabanovskaya ◽  
Yevgeniya Fesik ◽  
Yelena Slonimskaya ◽  
Irina Kondakova
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Treatment ◽  
Tumor Stage ◽  
Subunit Composition ◽  
Luminal Breast Cancer ◽  
Luminal A ◽  
Luminal B ◽  
Lymphogenous Metastasis ◽  
Total Pool ◽  
Lymphogenic Metastasis

The aim of this study was to investigate characteristics of the proteasomal system in luminal breast cancer. There were included 124 patients with primary luminal breast cancer in stage Т13N0-2M0 who had not received neoadjuvant treatment. The process of lymphogenous metastasis was associated with a significant change in caspase-like activity (CL) and subunit composition of proteasomes. CL activity of proteasomes was increased in luminal A breast cancer with extensive lymphogenic metastasis (N2), while it was decreased in the luminal B subtype of cancer. It was accompanied by an increase in the composition of the proteasomal total pool subunits, regulatory and immune subunits. Decrease in CL activity of proteasomes can be poor prognostic sign which is associated with the lymphogenous invasion of the tumor process in luminal B breast cancer.

Sign in / Sign up

Export Citation Format

Share Document